Limited ('Alebund' or the 'Company'), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, today ...
Guidance -- Confirmed unchanged 2026 outlook: revenue growth of 6%-8% and adjusted EPS growth of 15%-20%. Three-Year Targets -- Reiterated goals: 6%-8% GAAP revenue growth, 150 basis points of margin ...
Navy Media on MSN
U.S. Navy Destroyers: Multi-Domain Defense in the Western Pa
The Western Pacific has become the world’s most consequential maritime theater, where great power competition plays out ...
U.S. forces struck a target on Luzon in the Philippines earlier this week with a Tomahawk cruise missile in a ...
Microsoft Defender Research observed a large-scale credential theft campaign that exemplifies this trend, using code of ...
A single-cell platform reveals that many genetic mutations converge on shared cellular programs, pointing to simpler, more ...
Membrane proteins present significant technical challenges in drug discovery, yet their role in biology make them highly ...
Peter Gratton, Ph.D., is a New Orleans-based editor and professor with over 20 years of experience in investing, economics, and public policy. Peter began covering markets at Multex (Reuters) and has ...
Our multi-asset benchmarks are designed to provide broad measures of cross-asset market performance across the globe. Flagship indices include the Bloomberg Multi-Asset Index family which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results